Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies

OBJECTIVE: To estimate the 5-year budget impact (BI) on a US health plan of introducing sarilumab – a human immunoglobulin G1 anti-IL-6 receptor α monoclonal antibody – as combination treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or monotherapy in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrufino, Cheryl P, Munakata, Julie, Wei, Wenhui, Proudfoot, Clare, Kuznik, Andreas, Boklage, Susan H, Chen, Chieh-I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247948/
https://www.ncbi.nlm.nih.gov/pubmed/30532571
http://dx.doi.org/10.2147/CEOR.S163829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247948/
https://www.ncbi.nlm.nih.gov/pubmed/30532571
http://dx.doi.org/10.2147/CEOR.S163829

Ejemplares similares